Alder BioPharmaceuticals to Present at 26th Annual Piper Jaffray Healthcare Conference
26 nov. 2014 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment...
Data From Phase 2b Clinical Trial of Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Treatment of Active Psoriatic Arthritis, to be Presented at the American College of Rheumatology Annual Meeting
15 nov. 2014 16h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 15, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...
Alder BioPharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
04 nov. 2014 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment...
Alder BioPharmaceuticals Reports Third Quarter 2014 Financial and Operating Results
03 nov. 2014 16h03 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...
Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial of ALD403 for Preventative Treatment of Chronic Migraine
03 nov. 2014 16h01 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment...
Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2014 Financial and Operating Results
24 oct. 2014 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 24, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...
Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine
06 oct. 2014 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing antibody therapeutics, today announced data from the...
Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab
02 sept. 2014 07h00 HE
|
Alder BioPharmaceuticals, Inc.
Company Plans to Continue Development of Therapeutic Antibody for Autoimmune/Inflammatory Disease
Conference Call/Webcast Scheduled for 9 a.m. EDT Today
BOTHELL, Wash., Sept. 2, 2014 (GLOBE...
Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results
05 août 2014 16h02 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...
Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results
29 juil. 2014 07h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 29, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...